4,221 results on '"Ponikowski, Piotr"'
Search Results
2. Lymphatic Drainage in Patients with Heart Failure: A Feasibility Study
3. Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study
4. High-intensity care for GDMT titration
5. Role of dietary sodium restriction in chronic heart failure: systematic review and meta-analysis
6. The role of urine chloride in acute heart failure
7. Effectiveness of remote pulmonary artery pressure estimating in heart failure: systematic review and meta-analysis
8. Author Correction: Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure
9. Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure
10. Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure: Insights From the RELAX-AHF-2 Trial
11. EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER
12. The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial
13. Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial
14. Acute Heart Failure: Transitioning From Symptom-Based Care to Remission
15. Increasing Evidence Supports the Benefits of Rapid Uptitration of the Neurohormonal Blockade in HFmrEF/HFpEF Patients With AHF
16. Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
17. Abstract 4141380: The relationships between circulating biomarkers of iron deficiency and outcomes in patients with heart failure and reduced ejection fraction: insights from DAPA-HF.
18. Abstract 4140057: Defining Severe Heart Failure across the Ejection Fraction Spectrum in DAPA-HF and DELIVER
19. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2
20. Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis
21. Association of Reduced Left Atrial Reserve With Exercise Intolerance and Outcome in Hypertension
22. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial
23. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
24. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
25. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial
26. Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?
27. Iron deficiency in heart failure
28. Heart failure clinical assessment
29. Ancillary procedures
30. Inotropes and inodilators
31. Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF
32. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
33. Contribution of reduced skeletal muscle perfusion reserve to exercise intolerance in heart failure with preserved ejection fraction
34. Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial
35. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
36. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial
37. Relationship of Vascular Endothelial Growth Factor C, a Lymphangiogenesis Modulator, With Edema Formation, Congestion and Outcomes in Acute Heart Failure
38. Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial
39. Role of Lymphatics in Heart Failure
40. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
41. Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
42. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
43. Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic
44. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
45. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
46. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF
47. Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial
48. Global Rounds: Poland
49. Pressure–Volume Profiles in Heart Failure Across Sexes and Phenotypes
50. Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.